You the man big Z! How cool is it that out chief knows what he has and is going for big bucks, immunotherapy is where all the money is going. Big things coming, wow.
With regards to the exclusivity for IL-12 use, it looks like it is for direct tumor application. One of the most promising aspects of the early data, though, has been the systemic effects (shrinkage of tumors that were not treated directly). I wonder if there is any reason to think that the systemic effects depend on injection into a tumor vs. a muscle.
Very nice job brother; our convictions further confirmed. My own deduction that no-one can make a product like immunopulse (because of the university patents) is confirmed by Punit when he says that they're the only ones able to apply IL-12 inside tumors. INO's will necessarily have to be used to supplement their vac.
Extremely positive outlook overall, in the midst of growth and expansion. Awesome time to be a shareholder.
Z, great interview and thanks for taking the time to do it. I like that there are potential partners watching. This has been obvious for some time that bigger fish have been on the sidelines, imo.